BACKGROUND: Vancomycin susceptibility, the accessory gene global regulator (agr) genotype and function, staphylococcal cassette chromosome (SCC) mec type, and susceptibility to cationic thrombin-induced platelet microbicidal protein 1 (tPMP-1) have been individually predictive of duration of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. This investigation evaluated the interrelationship of these factors with time to clearance of MRSA bacteremia during vancomycin therapy in patients without endocarditis. METHODS: Vancomycin minimum inhibitory concentration and in vitro killing, agr function (delta-hemolysin activity), agr group, SCCmec type, and survival in tPMP-1 killing assays were determined for 29 MRSA bacteremia isolates. RESULTS: Increased resistance to tPMP-1 killing was observed with agr group III MRSA (P = .025) and MRSA with reduced or absent agr function (P = .023). The median time to clearance of MRSA bacteremia was earlier for agr group III (3 days) versus group I (10.5 days) or II (15 days) (P = .001). In multivariate analysis, agr group II, reduced tPMP-1 killing in vitro, and prior vancomycin exposure were significant independent predictors of longer MRSA bacteremia duration. CONCLUSIONS: Specific genotypic, phenotypic, and clinical parameters appear to correlate with persistent MRSA bacteremia. The interrelationship of these and other factors probably contributes to vancomycin-mediated clearance of MRSA bacteremia.
BACKGROUND:Vancomycin susceptibility, the accessory gene global regulator (agr) genotype and function, staphylococcal cassette chromosome (SCC) mec type, and susceptibility to cationic thrombin-induced platelet microbicidal protein 1 (tPMP-1) have been individually predictive of duration of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. This investigation evaluated the interrelationship of these factors with time to clearance of MRSA bacteremia during vancomycin therapy in patients without endocarditis. METHODS:Vancomycin minimum inhibitory concentration and in vitro killing, agr function (delta-hemolysin activity), agr group, SCCmec type, and survival in tPMP-1 killing assays were determined for 29 MRSA bacteremia isolates. RESULTS: Increased resistance to tPMP-1 killing was observed with agr group III MRSA (P = .025) and MRSA with reduced or absent agr function (P = .023). The median time to clearance of MRSA bacteremia was earlier for agr group III (3 days) versus group I (10.5 days) or II (15 days) (P = .001). In multivariate analysis, agr group II, reduced tPMP-1 killing in vitro, and prior vancomycin exposure were significant independent predictors of longer MRSA bacteremia duration. CONCLUSIONS: Specific genotypic, phenotypic, and clinical parameters appear to correlate with persistent MRSA bacteremia. The interrelationship of these and other factors probably contributes to vancomycin-mediated clearance of MRSA bacteremia.
Authors: Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine Journal: Am J Health Syst Pharm Date: 2009-01-01 Impact factor: 2.637
Authors: Carlo McCalla; Davida S Smyth; D Ashley Robinson; Judith Steenbergen; Steven A Luperchio; Pamela A Moise; Vance G Fowler; George Sakoulas Journal: Antimicrob Agents Chemother Date: 2008-07-07 Impact factor: 5.191
Authors: T P Lodise; C D Miller; J Graves; A Evans; E Graffunder; M Helmecke; K Stellrecht Journal: J Antimicrob Chemother Date: 2008-08-11 Impact factor: 5.790
Authors: Donald I Hsu; Levita K Hidayat; Ryan Quist; Janet Hindler; Asa Karlsson; Anne Yusof; Annie Wong-Beringer Journal: Int J Antimicrob Agents Date: 2008-08-12 Impact factor: 5.283
Authors: T P Lodise; J Graves; A Evans; E Graffunder; M Helmecke; B M Lomaestro; K Stellrecht Journal: Antimicrob Agents Chemother Date: 2008-06-30 Impact factor: 5.191
Authors: Pamela A Moise; Davida S Smyth; Nadia El-Fawal; D Ashley Robinson; Patricia N Holden; Alan Forrest; George Sakoulas Journal: J Antimicrob Chemother Date: 2007-11-27 Impact factor: 5.790
Authors: Kati Seidl; Arnold S Bayer; Vance G Fowler; James A McKinnell; Wessam Abdel Hady; George Sakoulas; Michael R Yeaman; Yan Q Xiong Journal: Antimicrob Agents Chemother Date: 2010-11-22 Impact factor: 5.191
Authors: Wessam Abdelhady; Liang Chen; Arnold S Bayer; Kati Seidl; Michael R Yeaman; Barry N Kreiswirth; Yan Q Xiong Journal: J Antimicrob Chemother Date: 2015-01-05 Impact factor: 5.790
Authors: Wei Gao; David R Cameron; John K Davies; Xenia Kostoulias; Justin Stepnell; Kellie L Tuck; Michael R Yeaman; Anton Y Peleg; Timothy P Stinear; Benjamin P Howden Journal: J Infect Dis Date: 2012-12-18 Impact factor: 5.226
Authors: Sarah E Hobdey; Eva J Katahira; Pamela Dockstader; Stephen M Davidson; Laura Bond; Devin D Bolz; Amy E Bryant; Dennis L Stevens Journal: Antimicrob Agents Chemother Date: 2017-10-24 Impact factor: 5.191
Authors: Kati Seidl; Liang Chen; Arnold S Bayer; Wessam Abdel Hady; Barry N Kreiswirth; Yan Q Xiong Journal: Antimicrob Agents Chemother Date: 2011-10-03 Impact factor: 5.191
Authors: Nagendra N Mishra; Arnold S Bayer; Pamela A Moise; Michael R Yeaman; George Sakoulas Journal: J Infect Dis Date: 2012-08-16 Impact factor: 5.226
Authors: Wei Gao; Kyra Chua; John K Davies; Hayley J Newton; Torsten Seemann; Paul F Harrison; Natasha E Holmes; Hyun-Woo Rhee; Jong-In Hong; Elizabeth L Hartland; Timothy P Stinear; Benjamin P Howden Journal: PLoS Pathog Date: 2010-06-10 Impact factor: 6.823
Authors: Arnold S Bayer; Nagendra N Mishra; George Sakoulas; Poochit Nonejuie; Cynthia C Nast; Joseph Pogliano; Kuan-Tsen Chen; Steven N Ellison; Michael R Yeaman; Soo-Jin Yang Journal: Antimicrob Agents Chemother Date: 2014-10-06 Impact factor: 5.191